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In Brief
Bekker-Jensen et al. show that
proteomics can now provide an
essentially complete HeLa proteome.
They provide measurements acquired
simultaneously for more than 12,200
protein-coding genes, 10,000
phosphorylation sites, and 7,000
N-acetylation sites. Their approach is
fast, accessible, and requires modest
amounts of starting material, making it
easily extendable to other human cell
lines and patient samples.
Cell Systems
ArticleAn Optimized Shotgun Strategy
for the Rapid Generation
of Comprehensive Human Proteomes
Dorte B. Bekker-Jensen,1,4 Christian D. Kelstrup,1,4,* Tanveer S. Batth,1 Sara C. Larsen,1 Christa Haldrup,2
Jesper B. Bramsen,2 Karina D. Sørensen,2 Søren Høyer,3 Torben F. Ørntoft,2 Claus L. Andersen,2 Michael L. Nielsen,1
and Jesper V. Olsen1,5,*
1Proteomics Program, Faculty of Health and Medical Sciences, Novo Nordisk Foundation Center for Protein Research, University of
Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark
2Departments of Molecular Medicine and Clinical Medicine, Aarhus University Hospital, Aarhus University, Palle Juul-Jensens Boulevard 99,
8200 Aarhus, Denmark
3Institute of Pathology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200 Aarhus, Denmark
4These authors contributed equally
5Lead Contact
*Correspondence: christian.kelstrup@cpr.ku.dk (C.D.K.), jesper.olsen@cpr.ku.dk (J.V.O.)
http://dx.doi.org/10.1016/j.cels.2017.05.009SUMMARY
This study investigates the challenge of comprehen-
sively cataloging the complete human proteome
from a single-cell type using mass spectrometry
(MS)-based shotgun proteomics. We modify a clas-
sical two-dimensional high-resolution reversed-
phase peptide fractionation scheme and optimize a
protocol that provides sufficient peak capacity to
saturate the sequencing speed of modern MS instru-
ments. This strategy enables the deepest proteome
of a human single-cell type to date, with the HeLa
proteome sequenced to a depth of 584,000 unique
peptide sequences and 14,200 protein isoforms
(12,200 protein-coding genes). This depth is com-
parable with next-generation RNA sequencing and
enables the identification of post-translational modi-
fications, including 7,000 N-acetylation sites and
10,000 phosphorylation sites, without the need for
enrichment. We further demonstrate the general
applicability and clinical potential of this proteomics
strategy by comprehensively quantifying global pro-
teome expression in several different human cancer
cell lines and patient tissue samples.
INTRODUCTION
Comprehensive proteomics describes the mass spectrometric
analysis of essentially all endogenously expressed proteins in a
cell, tissue, or organism. This is the ultimate goal for proteomics
studies, as it enables routine systems biology analyses and
biomarker discoveries (Eriksson and Fenyo, 2007). Tremendous
efforts by the proteomics community have already enabled
essentially complete proteome analysis of simpler organisms,
such as Baker’s yeast, with the first comprehensive analysis of
the yeast proteome achieved 9 years ago (de Godoy et al.,Cell Systems 4, 587–599, J
This is an open access article und2008). While it required a week of total mass spectrometry
(MS) instrument time to obtain this original data, the complete
yeast proteome can now be analyzed a hundred times faster,
in 1.8 hr (Hebert et al., 2014).
Efforts to map the complete human proteome have likewise
mainly been attempted by brute force analyses, where very
large-scale experiments have been carried out. This was, for
example, the case in the two recent initial drafts of the humanpro-
teome,where thousandsofMSanalysis runswerecombined (Kim
et al., 2014; Wilhelm et al., 2014). However, these datasets also
sparkedadebate in theproteomicscommunityabouthow tocon-
trol false discovery rates (FDRs) on the level of individual proteins;
that is estimating and minimizing error rates by correcting for
multi-hypothesis testing in large-scale datasets. Recent statisti-
cal developments and re-analysis of the data has since lowered
the original claims of proteome coverage (Ezkurdia et al., 2014;
Savitski et al., 2015; The et al., 2016).While these reanalyzed pro-
teome drafts demonstrate that comprehensive coverage of the
human proteome is possible even when FDR is controlled for,
they achieved these high protein numbers by combining analyses
of many different cell types, i.e., the proteome coverage of a sin-
gle-cell type was not extraordinary compared with other large-
scale studies (Iwasaki and Ishihama, 2014).
Deep proteome analysis of single human cell types has been
done by so-called ‘‘single’’-shot analysis where a single-dimen-
sion liquid chromatography (LC) is coupled to MS (LC-MS)
(Geiger et al., 2012). While ‘‘single’’-shot analysis is preferable
due to its simplicity and robustness, it will not achieve the
same depth compared with classic multidimensional fraction-
ation strategies where multiple fractionation schemes are used
in series such as LC/LC/MS and higher. This is due to the fact
that fractionation of peptides and proteins is a simple way to in-
crease peak capacity of the LC separation (Wolters et al., 2001).
In particular, offline peptide fractionation at high pH (HpH) prior
to low pH online in an LC/LC-MS setup has shown great promise
in recent years (Mertins et al., 2016; Wang et al., 2011). Another
emerging trend in deep proteome analysis has been tomake use
of ever longer online peptide separation gradients to boost iden-
tification numbers, but to benefit from this requires extremeune 28, 2017 ª 2017 The Author(s). Published by Elsevier Inc. 587
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1. Workflow Overview
(A) Conceptual strategy for improving the limit of detection through multiple
sample injections, increasing the peak capacity through multiple LC separa-
tions, maximizing ion flux and instrument time using short LC-MS gradients,
while keeping the MS in the fastest scanning mode.
(B) Experimental workflow of all HeLa experiments.
(C) Quantitative reproducibility of the method.
588 Cell Systems 4, 587–599, June 28, 2017chromatographic performance using very long analytical col-
umns (Iwasaki et al., 2012; Nagaraj et al., 2012). We have previ-
ously argued against longer gradients as this increases the time
window within which a peptide elutes and thereby naturally di-
lutes its apex peak intensity or ion flux, shifting the MS analysis
optimum to slower scanning MSmethods (Kelstrup et al., 2012).
Here, we present a readily approachable, optimized method
for generating deep proteomes. This method takes full advan-
tage of the high resolution that offline HpH fractionation provides
and combines it with short gradients and a fast 20 Hz scanning
tandemMS (MS/MS)method for subsequent proteome analysis.
This combination solves the problems of lower sensitivity usually
associated with fast scanning MS/MS methods, and we demon-
strate that the concept of running many fractions on short
gradients is the sweet-spot in terms of best compromise be-
tween instrument time used and sequencing depth obtained.
To benchmark this workflow we analyzed the human proteome
of the HeLa cervix carcinoma cell line, which is the most
commonly usedmodel for studying human cell biology (Masters,
2002). HeLa cells are also the most widely used human cell line
applied in proteomics studies (von Stechow et al., 2015), making
it the ideal model system for a reference proteome. Collectively
we identify more than 14,000 unique protein groups covering
12,200 protein-coding genes and demonstrate that the HeLa
proteome can be comprehensively analyzed to a depth similar
to that of next-generation RNA-seq technology. This method is
generally applicable, in that it accurately quantifies the pro-
teomes of other human cell lines as well as patient tissue biopsy
samples with similar proteome depth. Finally, we demonstrate
that the massive peptide sequencing simultaneously yields
deep coverage of the major post-translational modifications
(PTMs) without specific enrichment.
RESULTS
A multi-shot proteomics strategy is known to increase the dy-
namic range and coverage compared with single-shot experi-
ments in human proteome investigations. We hypothesized
that a strategy based on high sample amounts and offline pep-
tide pre-fractionation collecting high numbers of fractions in
combination with short LC-MS/MS gradients and high peptide
sequencing speed would overcome many of the inherent dy-
namic range issues in proteomics without compromising the
overall analysis time required. We reasoned that optimization
and maximization of each of the four interconnected technical
parameters were needed (Figure 1A). First, we wanted to
improve the detection limit by increasing total peptide amounts
analyzed. Since the maximal loading capacity of our online
nano-scale LC-MS system, without significant loss in chromato-
graphic performance or peptide identifications (Kelstrup et al.,
2014), is around 1 mg on the column, the use ofmultiple injections
is a way to indirectly increase the loading capacity. Second, to
increase peak capacity and effectively separate milligrams of
complex peptide mixtures into multiple fractions we utilized
high-capacity offline HpH reversed-phase LCwith high resolving
power generating numerous (39–70) fractions containing large
peptide amounts and with minimum overlap between individual
fractions. Third, to decrease peak widths and increaseMS signal
intensity of analyzed peptides and simultaneously decrease
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Figure 2. Workflow Performance Charac-
teristics
(A) Visualization of peptide sequencing speed
analyzing HpH fraction 46.
(B) Cumulative number of proteins and protein-
coding genes through HpH fraction 46.
(C) Histogram illustrating LC peak width distribu-
tions for all multi-charged isotope patterns, tar-
geted precursors, and identified peptides.
(D) Heatmap representing the orthogonality of LC
separations through binning of both dimensions
by minutes.
(E) Visualization of peptide overlap between HpH
fractions.overall MS analysis time, we optimized a short 30 min gradient
for online LC-MS, and minimized the loading, washing, column
equilibration, and other overheads between injections to
15 min. The 30 min gradient provided the best compromise be-
tween maximizing the number of unique peptides identified,
while maintaining high identification rates when benchmarked
against longer and shorter gradients (Figure S1). Fourth, to
cope with the fast chromatographic separations we made use
of the fastest scanning higher-energy collisional dissociation
(HCD) (Olsen et al., 2007) MS/MS with 20 Hz orbitrap acquisition
rates. This method leveraged the increased MS signal inten-
sities, thereby achieving overall peptide identification rates of
approximately 40% with high identification scores (Figure S2).
We initially optimized peptide fractionation and MS analysis
workflow with total cell lysates derived from the commonlyCeused HeLa cell line, testing different frac-
tionation schemes and proteases (Fig-
ure 1B). In brief, adherent HeLa cells
were efficiently lysed by boiling directly
in a GndCl buffer and extracted proteins
digested overnight. Aliquots of 1 mg of
the resulting peptides were fractionated
by offline HpH reversed-phase chroma-
tography (Batth et al., 2014) without
fraction concatenation, and each fraction
was analyzed by online LC-MS/MS using
a Q-Exactive HF orbitrap instrument in
the fastest HCD scanningmode (Kelstrup
et al., 2014) (Figure 1B). Analyzing 1 mg of
HeLa peptides on the column from each
of 46 HpH fractions with 30 min LC-MS/
MS gradients (45 min run-to-run), using
a total of 34.5 hr resulted in identification
of 166,620 unique peptide sequences
covering 11,292 protein groups or 10,284
protein-coding genes. No matter how the
sample was fractionated, reproducibility
in terms of measured absolute protein
abundances between experiments was
high with Pearson correlation coefficients
of around 0.9 (Figure 1C). To determine
the inter-sample variability, we compared
the two biological HeLa replicates, 46
and 70 fractions, respectively, and foundroughly half of the proteins to have coefficients of variation of
less than 20%.
A key aspect to achieve this deep proteome coverage was the
high peptide loads together with short gradients and a very fast
scanning speed of the instruments, with more than 1,000 MS/
MS per minute, of which more than 40% on average could be
identified (Figure 2A). If the utmost speed in analysis is required,
it is possible to identify more than 4,000 protein groups in a single
fraction (Figure 2B). The fast gradient together with high-resolu-
tion online chromatography enabled a median peak full width
half maximum of 3.64 s of identified precursors. Assuming a
roughly Gaussian peak shape and a classic definition of full
peak width equal to 4 SDs, the median peak full width is
on average 6.2 s and the resulting peak capacity for each
fraction can be estimated around 290 (Figure 2C). This is notll Systems 4, 587–599, June 28, 2017 589
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Figure 3. Comprehensive Analysis of the
HeLa Proteome
(A) Identifications based on replica digests and
alternative proteases for peptides, protein-coding
genes, and proteins, including isoforms.
(B) Comparison of sequence coverage achieved.
(C) Benchmarking this HeLa dataset against
other published datasets of deep single-cell pro-
teomes. Bar chart showing comparisons of unique
peptide sequences identified per minute of anal-
ysis time and peptides per protein.extraordinarily impressive, but when 46 fractions are analyzed
together this translates into a very high peak capacity estimation
of 13,300. The lack of full orthogonality between separations in the
two LC dimensions lowers the actual peak capacity value (Fig-
ure 2D), but it is still one order of magnitude higher than the
best one-dimensional LC separations that may approach a peak
capacity of 1,000 on long columns/gradients (Shishkova et al.,
2016). The offline HpH fractionation was performed with high res-
olution, as 82%of peptide spectrummatches and 75%of peptide
sequences were unique to a single HpH fraction, and a further
17% of peptide sequences were only found in two fractions as590 Cell Systems 4, 587–599, June 28, 2017indicated by the gray scale in the graph-
ical representation (Figure 2E). When
increasing the number of fractions from
46 to 70, the peptide sequences unique
to one fraction dropped from 75% to
61%, and the corresponding peptide
and protein identifications are therefore
not vastly higher, but total analysis time
needed increased by 50% (Table S1).
Utilizing alternative proteases to trypsin
has previously been demonstrated as a
means to reveal an undetected part of
the proteome and increase proteome
coverage (Giansanti et al., 2015, 2016;
Guo et al., 2014; Low et al., 2013; Swaney
et al., 2010). Therefore, we tested the
benefits of using Glu-C, Lys-C, and
chymotrypsin as alternative proteases to
trypsin using the multi-shot proteomics
workflow. For a single sample, trypsin
identified the highest number of both
peptides and proteins (Figure S3). This
is not surprising as trypsin is historically
the preferred protease used in most
shotgun proteomics studies due to its
properties of generating peptides with
predictable cleavage patterns (Olsen
et al., 2004) that fragment very well in
MS. When combining the analyses of all
six tryptic digests, we identify 361,000
unique tryptic peptide sequences map-
ping to 11,900 unique protein-coding
genes and 13,600 unique proteins. Add-
ing the additional 223,000 unique pep-
tides from the three other proteasesresults in a total of 584,000 unique peptide sequences from
HeLa cells (Table S2), which is more than those presented in
the recent organ-wide drafts of the human proteome (Kim et al.,
2014; Wilhelm et al., 2014) (Table S1). The unique peptides from
the additional proteases increased the total number of covered
protein-coding genes by 300 to a total of 12,200 and they pro-
vided increased coverage of protein isoforms by twice as much
to a total of 14,200 (Figures 3A and S3). Another way to evaluate
proteome coverage is by calculating the average amino acid
coverage per protein achieved. Adding the 223,000 unique pep-
tide sequences from the alternative protease datasets increases
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Figure 4. Functional Analysis of the HeLa
Proteome
(A) Comparison of protein-coding gene abun-
dances in HeLa identified in this dataset with the
largest existing HeLa proteome published so far.
(B) Comparison of protein-coding genes identified
in HeLa in this dataset with previously published
proteome and next-generation RNA-seq data of
HeLa cells.
(C) CORUM protein complex coverage of the
identified proteins in this dataset.
(D) Abundance of BRCA1/RNA polymerase II
complex members in HeLa cells visualized ac-
cording to their individual protein intensities.
(E) Abundance of proteasomal proteins in HeLa
visualized according to their individual protein
intensities.
(F) Scatterplot of HeLa protein copy-number
estimation from this dataset with previously pub-
lished copy numbers.the average sequence coverage to 52% (Figure 3B). A simple
amino acid count of the 584,000 unique peptides relative to the
count of sequences from the identified protein-coding genes re-
sults in a ratio of 1.44, also highlighting that a significant overlap
is observed among the peptide sequences.
Previously published studies (Arabi et al., 2012; Beck et al.,
2011; Boisvert et al., 2012; Branca et al., 2014; Guo et al., 2014;
Iwasaki et al., 2012; Nagaraj et al., 2011; Spicer et al., 2016; Tha-
kur et al., 2011; Ting et al., 2011; VanHoof et al., 2009;Wisniewski
et al., 2009; Yamana et al., 2013) have also provided deep prote-
ome coverage of single human cell types with high peptide
coverage. However, this has typically been done at the expense
of pro-longed acquisition time, whereas studies focusing on
high protein coverage using shorterMSanalysis timegenerally re-Cesults in low overall peptide coverage.
Conversely, our study demonstrates that
this analytical strategy makes it possible
to achieve high protein coverage with
short MS analysis time (Figure 3C).
The combined deep HeLa proteome
presented here expands the previous re-
cord by a third, as more than 3,000 low
abundant protein-coding genes are now
identified of which many are receptors
and transcription factors (Figure 4A
and Table S3). Furthermore, our HeLa
dataset of 12,200 protein-coding genes
have comparable coverage with next-
generation RNA-seq data of the HeLa
cells (Figure 4B) (Nagaraj et al., 2011).
RNA-seq provided evidence for expres-
sion of close to 90% of the HeLa proteins
detected by MS and vice versa. As ex-
pected, the unique subsets of both data-
sets are biased toward low abundance.
Although these analyses suggest that
our coverage of the HeLa proteome is
quite complete, an alternative way toassess the completeness of a proteome is to quantify the
coverage of known macromolecular protein complexes. Most
macromolecular complexes were completely covered in our
HeLa proteome, and typically more than 90% of the members
of low-abundance cellular machineries were quantified, as esti-
mated by the detection of known protein complexes described
in the CORUM database (Ruepp et al., 2008) (Figure 4C and
Table S4). The complexes listed within CORUM that are not pre-
sent in HeLa cells, which were originally taken from cancerous
cervix, are largely cell-type-specific complexes encompassing
neuronal and immune specific proteins. Combining the protein
abundance estimates for proteins with information about the
macromolecular complex they belong to can be quite informa-
tive as this indirectly reveals the stoichiometry of individualll Systems 4, 587–599, June 28, 2017 591
complex components. This is exemplified by the BRCA1/RNA
polymerase II complex (Figure 4D) and the broad abundance dis-
tribution of proteins belonging to the different proteasome types
(Figure 4E). For example, the three specific subunits of the immu-
noproteasome are orders of magnitude lower in expression
compared with their counterparts in the constitutive proteasome
(Figure 4E). Consequently, the immunoproteasome must be at
least a 100-fold less abundant than the constitutive proteasome
in HeLa cells. Moreover, there is a significant abundance differ-
ence between the individual immunoproteasomal subunits as
PSBM8 (b5i) is 10-fold more abundant than the two other sub-
units, PSBM9 (b1i) and PSBM10 (b2i). This supports the pres-
ence of multiple intermediary immunoproteasomal units as
previously suggested (Guillaume et al., 2010). Based on these
comparative analyses of mRNA data and protein complexes,
we conclude that the expressed HeLa proteome analyzed here
is essentially complete.
Such quantitative analysis enables absolute quantitation of
protein copy numbers. The intensity-based absolute quantita-
tion (iBAQ) of proteins analyzed by shotgun proteomics data
has been shown to provide a reasonably accurate estimate of
protein copy numbers (Schwanhausser et al., 2011). The iBAQ
values are calculated by summing all peptide intensities for a
protein and dividing this by the number of theoretical tryptic
peptides between 6 and 30 amino acids in length to correct for
protein size. Moreover, precise copy numbers for a small set of
proteins in HeLa cells spanning the entire expression range
have been established (Hanke et al., 2008; Wisniewski et al.,
2014; Zeiler et al., 2012). Comparing the protein iBAQ values
calculated for our complete HeLa dataset with the previously es-
tablished HeLa protein copy numbers in log-space, we find a
strong linear correlation with Pearson correlation coefficient of
0.95 (Figure 4F). Accordingly, from this we can determine the
copy number of all 12,000 quantified proteins in HeLa cells sim-
ply by subtracting a log10 value of roughly 3.3 from our log10-
transformed iBAQ values.
Deep PTM Analysis without Enrichment
This comprehensive proteome also facilitates observation of
PTMs, including specific proteolytic cleavage, phosphorylation,
and N-acetylation. For example, the N terminus of proteins is
usually the most accessible part and this is often post-transla-
tionally processed by proteolytic cleavage of a signal peptide
ormodified by acetylation. Determining the sequence and nature
of protein N termini therefore provides important functional
annotation of proteins. We identified the peptide covering the
N termini of more than half of the proteins and the absence of
detection of N termini peptides from approximately 2,000 pro-
teins can readily be explained by known proteolytic processing
events such as removal of signal peptides and transit peptides
(Figure S4).
Although global analysis of any PTM by MS/MS usually re-
quires specific enrichment of the PTM-bearing peptides from to-
tal cell digests, we speculated that large-scale identification of
PTMs without specific enrichment should be possible. To test
this hypothesis, we searched our HeLa dataset for the major
intra-cellular PTMs, including site-specific phosphorylation,
acetylation, and methylation. From this analysis we identified
18,237 unique PTM sites (Table S5), including more than592 Cell Systems 4, 587–599, June 28, 201710,000 phosphorylation sites and more than 5,000 N-acetylation
sites. For protein N-acetylation, the coverage of sites is at the
same level as focused enrichment-based investigations (Kleifeld
et al., 2010), and for phosphorylation the coverage is high
enough to use system level analysis tools. For example, the en-
zymes that catalyze the addition or removal of PTMs often
achieve their cellular selectivity by having specificity toward
linear sequence motifs in substrate proteins (Puntervoll et al.,
2003). To identify enriched sequence motifs among the individ-
ual PTM sites identified we used the iceLogo software tool (Co-
laert et al., 2009). This analysis revealed strong overrepresenta-
tion of proline-directed phosphorylation of serine/threonine sites
and N-terminal protein acetylation of methionine, alanine, and
serine residues (Figure 5A). These observations are in line with
previous large-scale proteomics studies of these PTMs reflect-
ing well-known biology, for example the generally high cellular
activity and abundance of proline-directed kinases, such as
CDKs and MAPKs (Huttlin et al., 2010; Lundby et al., 2012).
Since phosphorylation was themost abundant PTM identified,
we determined the completeness of theHeLa phosphoproteome
that we achieved without specific enrichment. For comparison,
we performed HpH fractionation of a tryptic HeLa digest and en-
riched phosphopeptides from concatenated fractions using TiO2
(Batth et al., 2014). From three replicates we identified 30,304
unique phosphorylation sites. This phosphoproteome coverage
is close to the deepest analysis of the HeLa phosphoproteome
to date, where 38,203 sites were identified by multiple treat-
ments and enrichment strategies (Sharma et al., 2014). Merging
these datasets results in a fairly low overlap where the combined
HeLa phosphoproteome can be said to contain at least 51,291
phosphorylation sites (Figure S5). Importantly, this indicates
that even with enrichment, phosphoproteomics is not close to
completeness yet.
Despite the incomplete phosphoproteome coverage without
the use of specific phosphopeptide enrichment, quantitative re-
lationships can be derived directly from these data. For example,
we calculated the fractional stoichiometry of the individual iden-
tified phosphorylation sites by comparing them with their corre-
sponding non-phosphorylated counterpart peptides (Olsen
et al., 2010; Sharma et al., 2014). Given the general high
sequence coverage we could estimate the stoichiometry for
the majority of the phosphorylation sites identified without spe-
cific enrichment. The fractional stoichiometry of the sites we
identify without specific enrichment were found to be inversely
proportional to the abundance of the corresponding protein (Fig-
ure 5B). This verifies that we have an abundance bias as sites of
low stoichiometry can only be detected on proteins of high abun-
dance and vice versa. Despite this bias, interesting interpreta-
tions could bemade, and these allowed us to determine if protein
kinases have any preferences with regard to the cellular abun-
dance of their substrates. Unsupervised clustering of the HeLa
phosphorylation site stoichiometries and their corresponding
protein iBAQ values resulted in four main clusters (Figure 5C).
Kinase motif analysis of each of the four clusters revealed signif-
icant overrepresentation of casein kinase 2 (CK2) substrates in
the cluster representing high abundance proteins with high
site stoichiometry. This reflects the well-known biology of CK2
that is a ubiquitous, highly pleiotropic, and constitutively active
enzyme (Meggio and Pinna, 2003), and therefore phosphorylates
CH
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Figure 5. Post-Translational Modifications, PTMs, Identified in HeLa
(A) Sequence logo plots of major PTMs identified in HeLa without specific enrichment.
(B) Correlation between protein abundance and phosphorylation site stoichiometry.
(C) Kinasemotif enrichment analysis of four sub-clusters found by comparison of phosphorylation site stoichiometry and their corresponding protein abundance.
(D) Boxplot analysis of citations associated with phosphorylation sites in the four sub-clusters.its substrates to full site stoichiometry. Conversely, kinase motif
analysis of the cluster presenting proteins of high abundance
with low phosphorylation site stoichiometry indicated overrepre-
sentation of targets of cell-cycle kinases and DNA damage-
response kinases, which are in line with observations from previ-
ous studies (Olsen et al., 2010). Notably, the cluster analysis also
suggests that proline-directed kinases and baseophilic kinases
generally phosphorylate sites on proteins of low abundance to
high stoichiometry.
Since its introduction a decade ago global phosphoproteo-
mics has revolutionized the cell signaling field and has become
a standard technology accessible in many laboratories produc-
ing a wealth of publications (von Stechow et al., 2015). A site-
specific citation index can therefore be calculated indicating
how frequently a phosphorylation site is reported in the literature
(Hornbeck et al., 2004). When this analysis is applied to our clus-
ters of sites, a strong dependence between the site citation index
and the abundance of the site and its corresponding protein is
revealed (Figure 5D). In other words, low stoichiometry phos-
phorylation sites in HeLa cells are less studied in the general liter-
ature compared with sites we find to be of high abundance. As
control, we performed a similar analysis on the proteome as pro-
tein citation counts are available (Szklarczyk et al., 2015). This
analysis failed to find any dependence between the protein
abundance in HeLa cells with how studied the protein is. Collec-
tively, these analyses suggest that future technical challenges
specific to phosphoproteomics may arise from this strong abun-
dance bias we find in phosphoproteomics investigations re-
ported so far.
Comprehensive Proteome Analysis of Human Cell Lines
and Patient Samples
To assess the general applicability and quantitative accuracy of
this trypsin-based multi-shot proteomics workflow, we applied itto five additional cancer cell lines and patient biopsy samples
from three different organs (Figure 6A). From all cell lines and tis-
sue samples we collectively identify 724,780 unique peptides,
15,984 protein groups, and 13,446 protein-coding genes (Tables
S2, S6, and S7). This deep and comprehensive coverage of pep-
tides and proteins for other cell lines and tissues is similar to the
numbers achieved for a comparable single HeLa analysis
(Tables S7 and S8). Hierarchical clustering of the label-free quan-
titation values for all detected proteins across six different cell
lines revealed high reproducibility between biological replicates
with Pearson correlation coefficients above 0.95 (Figure 6B).
We observe that the HEK293 cell proteome expression profile
was most similar to that of SY5Y neuroblastoma cells, while
the other four cell lines form a separate group. A neuronal
expression phenotype of HEK293 cells has been reported previ-
ously, which could potentially explain this observation (Shaw
et al., 2002). The protein expression profiles for these cancer
cell lines are overall very comparable, but important differences
are present. Analyzing the expression differences of proteins
that are members of specific cellular signaling pathways, such
as the cell-cycle network, reveals quantitative differences across
the cell lines (Figure 6C). Large abundance differences are
observed for key proteins, such as p53, CDN1A, and several pro-
tein kinases, indicating a total rewiring of cell division control sys-
tems in the individual cell lines. Some of these differences may
be known (for example, the high expression level of p53 in
HEK293 compared with the other cell lines), but such deep
proteome coverage can be used to quantify globally how pertur-
bations of a cellular signaling network may impact protein
expression in cancer cell lines.
Notably, this proteomics workflow works equally well to hu-
man tissues yielding a similar coverage of peptides and proteins
(Table S8). Overlapping our tissue proteomes of liver, colon, and
prostate with previously published datasets demonstrates thatCell Systems 4, 587–599, June 28, 2017 593
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Figure 7. Large-Scale Analysis
(A) Venn diagram showing overlap between pro-
teins with N-acetylation identified in this dataset
and annotations in UniProt.
(B) Cellular compartment gene ontology enrich-
ment analysis of the N-acetylated proteome
compared with the non-acetylated proteome.
(C) Comparison of observed versus theoretical
tryptic peptides from the 12,209 protein-coding
genes found in HeLa as a function of peptide
length.
(D) Fractional coverage of the theoretical peptide
space in HeLa.
(E) Comparison of this dataset with published
large-scale proteome datasets with more than
6,500 proteins.proteome depth of all tissues is increased by thousands of pro-
teins, for example increasing the human colon tissue proteome
by an additional 4,400 proteins to 10,500 protein-coding genes
(Figure 6D). Next-generation RNA-seq of the same colon patient(D) Overlap of protein-coding genes identified in colon tissue using this method with a previously published
(E) Overlap of colon transcriptome and proteome from the same patient sample.
(F) Scatterplot of colon protein copy-number estimates and RNA-seq fragments per kilobase of transcript pe
(G) Histogram of colon RNA-seq (FPKM) with corresponding proteome copy-number estimates.
Cebiopsy combined with a stringent cutoff
criteria (fragments per kilobase of tran-
script per million mapped reads >1) pro-
vides evidence for expression of 13,347
different gene products (Figure 6E). This
is more genes than we find to be ex-
pressed at the protein level, most likely
due to only a single replicate being
analyzed for each proteome analysis.
Despite this limitation, however, the
method provides similar depth of the
obtained tissue proteomes as those
achieved for the cancer cell lines. For a
holistic view it is important to analyze
both mRNA and protein abundances in
parallel as the correlation between gene
expression measured by RNA-seq and
protein copy numbers estimated by MS
was weak, with a Pearson correlation
coefficient of 0.52 (Figure 6F). Similar
observations have been reported previ-
ously (Schwanhausser et al., 2011) in
part due to the difference in protein
and RNA abundance distribution profiles
(Figure 6G).
Collectively our dataset provides a
comprehensive resource of high-quality
peptide and protein identification and
quantitation, which can bemined compu-
tationally for new biology. For example,
combining all our datasets with the com-
plete human UniProt database reveals an
N-acetylated human proteome of morethan 7,000 sites of which the majority is covered in the six cell
lines analyzed here (Figure 7A). We find N-acetylation sites to
be highly enriched on nuclear and cytoplasmic proteins by
gene ontology analysis, whereas mitochondrial, extracellular,in-depth colon dataset.
r million mapped reads (FPKM) values.
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and membrane proteins are strongly underrepresented (Fig-
ure 7B). Combining all tryptic datasets further underscores the
very comprehensive coverage of theoretical tryptic peptides we
achieve (Figure 7C). This entire LC-MS workflow is greatly opti-
mized for typical tryptic peptides of length 10–14 as we cover
more than 70% of all predicted tryptic peptides in this range (Fig-
ure 7D). The combined dataset of only six cell lines and three
tissues represents the largest coverage of human proteins and
peptides frommulti-proteome studies to date (Figure 7E). Impor-
tantly, although this workflow has been optimized for starting
amounts of 1 mg of peptides, it works equally well for 10-fold
lower starting material (Figure S6). This makes it applicable to
minute amounts of samples, for example from fluorescence-acti-
vated cell-sorted cell populations. The only downside of using
less starting material is a significant drop in the number of
PTMs, such as phosphorylation sites.
DISCUSSION
The multi-shot proteomics methodological approach presented
here represents a straightforward strategy for comprehensive
analysis of human proteomes. We circumvent the inherent large
dynamic range issues of human proteomes by significantly
increasing the peak and loading capacity of our LC-MS system
while maintaining overall analysis time. This is achieved by
high-resolution offline HpH reversed-phase chromatography
with high peptide loads, and collecting a high number of fractions
that in turn are analyzed by online low pH LC-MS/MS using fast
gradients and fastest peptide sequencing speed. While it has
been demonstrated previously that offline HpH reversed-phase
fractionation of peptide mixtures in combination with online
low pH LC-MS is a powerful technology for deep proteome anal-
ysis to a depth of 11,466 protein-coding genes across 20 breast
cancer cell lines and 4 tissues (Lawrence et al., 2015), and 12,405
protein-coding genes across 105 tumor samples (Mertins et al.,
2016), this study optimizes all parts of the shotgun proteomics
workflow to achieve coverage of 12,209 protein-coding genes
in a single human cell line covering essentially all expressed pro-
teins and 13,446 protein-coding genes across 6 cell lines and 3
tissues.
An important aspect of deep proteome analysis is control of
FDR on protein level as recently debated (Savitski et al., 2015).
The MaxQuant software that we used here calculates protein
group scores and estimates FDR on both peptide and protein
levels, providing an estimate of expected misidentifications at
a global level. The publication by Ezkurdia et al. (2014) intro-
duced a simple quality test of large-scale proteome data using
the olfactory receptor family. The authors argued that a high-
quality proteomics experiment that does not specifically analyze
nasal tissues should not expect to detect many peptides for
olfactory receptors. Our combined dataset of six cell lines and
three tissues presented here, does not contain any olfactory re-
ceptors at the 1% protein FDR level, which therefore suggests
that it is of a similarly high-quality.
In total, the HeLa proteome presented here represents the first
analysis of a human cell line with coverage of protein-coding
genes comparable with that of next-generation RNA-seq tech-
nologies. Importantly, we demonstrate that our deep compre-
hensive HeLa proteome is acquired with high quantitative596 Cell Systems 4, 587–599, June 28, 2017accuracy and that this is independent of the number of offline
fractions collected and analyzed. This allowed us to determine
the copy number of 14,200 proteins in growing HeLa cells. Given
that our dataset represents the largest coverage of tryptic
peptides from human proteins to date, it serves as a useful
resource of high-resolution MS/MS spectra for the proteomics
community. For example, the dataset can be used to generate
high-quality and comprehensive spectral libraries for future
proteomics experiments. In a recent publication presenting the
Human SRMatlas, spectral libraries of 166,174 proteotypic
tryptic peptides from all human protein-coding genes were
generated by peptide synthesis and MS/MS analyses using
quadrupole time-of-flight and triple quadrupole type mass spec-
trometers (Kusebauch et al., 2016). Here we cover 108,573
of these proteotypic peptides representing two-thirds of the
Human SRMatlas, which is the same as our fractional coverage
of all human protein-coding genes.
An additional outcome of our deep proteome and improved
protein sequence coverage is that we identify thousands of
PTMs including more than 10,000 phosphorylation sites. Such
deep and broad PTM site coverage normally requires applica-
tion of specific enrichment strategies in a sequential manner
and extensive MS analysis time (Francavilla et al., 2016; Mertins
et al., 2013; Swaney et al., 2013), but comes for free with the
proteomics workflow presented here. This multi-shot prote-
omics strategy opens the possibility to study many PTMs simul-
taneously and estimate their stoichiometry directly (Olsen and
Mann, 2013), enabling investigations of PTM crosstalk, an
emerging theme in biology (Hunter, 2007), thus providing bio-
logical insights into the integrated and complex cell signaling
layers.
A current limitation of this approach is that we are still missing
comprehensive depth in PTM analysis and quantitative accuracy
for proteins of low abundance. But this can likely be addressed in
the next generation of MS instrumentation with faster peptide
sequencing speed, sensitivity, and increased dynamic range.
Nevertheless, we demonstrated the power of this proteomics
workflow by applying it to analyze human proteomes from a va-
riety of sample types, including different cancer cell lines and pa-
tient organ biopsies. These experiments firmly established the
capability of this proteomics strategy delineated here to compre-
hensively and quantitatively analyze protein expression differ-
ences between different cell states. Therefore, the experimental
workflow outlined here should be applicable to comprehensively
analyze any mammalian cell or tissue proteome in a quantitative
manner with sufficient throughput for clinical applications with
larger patient cohorts.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cells
Human epithelial cervix carcinoma HeLa cells (female), human embryonic kidney HEK293 cells (fetus), human neuroblastoma
SH-SY5Y cells (female), lung adenocarcinoma A549 cells (male), human colon cancer HTC116 cells and human breast cancer
MCF-7 cells (female) were purchased from ATCC. Cells were cultured in DMEM (Gibco, Invitrogen), supplemented with 10% fetal
bovine serum, 100U/mL penicillin (Invitrogen), 100mg/mL streptomycin (Invitrogen), at 37C, in a humidified incubator with 5%
CO2. SH-SY5Ywas cultured in RPMI (Gibco, Invitrogen) with the same supplements as listed above.We have not performed specific
authentication of the cell lines used in this study.
Patient Tissue Sample Biopsies
Collection and use of the human samples provided by Department of Molecular Medicine, Aarhus University Hospital, Aarhus,
Denmark has been approved by The Central Denmark Region Committees on Health Research Ethics (J. no‟s M-1999/4678 and
M-2000/0299). Informed consent was obtained from all donors. Use of clinical data associated with the samples has been approved
by the Danish Data protection Agency (j. no 2007-58-0010 and j.no. 2013-41-2041). Total RNA from serial cryosections were ex-
tracted using the RNeasy Mini Kit (Qiagen). RNA integrity was assessed using the Agilent RNA 6000 Nano Kit on an Agilent 2100 Bio-
analyzer and the analyzed samples had RNA integrity numbers (RIN) >9.
METHOD DETAILS
Cell Lysis
Cells were harvested at approximately 80%confluency bywashing twice with PBS (Gibco, Life technologies) and subsequently add-
ing boiling lysis buffer (6 M guanidinium hydrochloride (GndCl), 5 mM tris(2-carboxyethyl)phosphine, 10 mM chloroacetamide,
100mMTris, pH 8.5) directly to the plate. Cells were collected by scraping the plate and boiled for additional 10min followed bymicro
tip sonication.
Tissue Homogenization
Human tissues were quickly dissected and snap frozen. Followed by heat inactivation (Denator T1 Heat Stabilizor, Denator) the tis-
sues were transferred to a GndCl solution (6 M GndCl, 25 mM Tris, pH 8.5, Roche Complete Protease Inhibitor tablets (Roche)) and
homogenized by ceramic beads using 2 steps of 20 s at 5500 rpm (Precellys 24, Bertin Technologies). The tissues were heated for
10 min at 95 C followed by micro tip sonication on ice and clarified by centrifugation (20 min, 16,000g, 4 C). Samples were reduced
and alkylated by adding 5 mM tris(2-carboxyethyl)phosphine and 10 mM chloroacetamide for 20 min at room temperature.
Sample Preparation
Protein concentration was estimated by Bradford assay (Bio-Rad), and the lysates were digested with Lys-C (Wako) in an
enzyme/protein ratio of 1:100 (w/w) for 1 h followed by a threefold dilution with 25 mM Tris, pH 8.5, to 2 M GndCl and further
digested overnight with trypsin (Sigma Aldrich) 1:100 (w/w). For experiments using different proteases, lysates were directly
diluted to 2 M GndCl before addition of proteases (Lys-C, Trypsin, Chymotrypsin (Roche) and Glu-C (Roche)). Protease activity
was quenched by acidification with trifluoroacetic acid (TFA) to a final concentration of approximately 1%, and the resulting pep-
tide mixture was concentrated using reversed-phase Sep-Pak C18 Cartridge (Waters). Peptides were eluted off the Sep-Pak with
2 mL 40% acetonitrile (ACN) followed by 2 mL 60% ACN. The ACN was removed by vacuum centrifugation for 40 min at 60 C
and the final peptide concentration was estimated by measuring absorbance at 280 nm on a NanoDrop (NanoDrop 2000C,
Thermo Scientific).Cell Systems 4, 587–599.e1–e4, June 28, 2017 e2
Offline High pH Reversed-Phase HPLC Fractionation
1-2 mg of peptides were fractionated using a Waters XBridge BEH130 C18 3.5 mm 4.63 250 mm column on an Ultimate 3000 high-
pressure liquid chromatography (HPLC) system (Dionex, Sunnyvale, CA, USA) operating at a flow rate of 1 mL/min with three buffer
lines: Buffer A consisting of water, buffer B of ACN and Buffer C of 25mMAmmonium bicarbonate, pH8. Peptides were separated by
a linear gradient from 5%B to 35%B in 62min followed by a linear increase to 60%B in 5min, and ramped to 70%B in 3min. Buffer C
was constantly introduced throughout the gradient at 10%. Fractions were collected at 60 s or 90 s intervals to a total of either 39, 46,
or 70 fractions. Samples were acidified with formic acid to a final concentration of approximately 0.1% prior to concentration using
vacuum centrifugation. For nanoflow LC–MS/MS, the loading amount was kept constant at 1 mg per injection, estimated by
measuring absorbance at 280 nm on a NanoDrop instrument.
Phosphopeptide Enrichment
Phosphopeptides from all 46 fractions were enriched using titanium dioxide beads (5 mm Titansphere, GL Sciences, Japan). TiO2
beads were pre-incubated in 2,5-dihydroxybenzoic acid (20 mg/mL) in 80%ACN and 1%TFA (5 mL/mg of beads) for 20 min. All frac-
tionswere brought to 80%ACNand 5%TFA in a final volume of 5mL. 1mg (in 5mL of DHB solution) was added to each fraction, which
was then incubated for 30 min while rotating. After incubation, fractions were transferred to a deep 96-well filter plate and the super-
natant was removed by a vacuummanifold and collected to four new fractions with a traditional concatenation scheme. These were
incubated with fresh TiO2 beads for a second enrichment step. Beads were washed on the filter plate with 1 mL 80% ACN and 1%
TFA, followed by 50%ACN and 1% TFA. The final washing step was with 10% ACN and 1% TFA. The phosphopeptides were eluted
from the plate with 400 mL 5% NH4OH followed by 400 mL 10% NH4OH with 25% ACN. Eluted peptides were concentrated in a
speed-vac and loaded onto C18 Stage-tips.
Nanoflow LC–MS/MS
All samples were analyzed on an Easy-nLC 1000 coupled to a Q-Exactive HF instrument (Thermo Fisher Scientific) equipped with a
nanoelectrospray source. Peptideswere separated on a 15 cmanalytical column (75 mm inner diameter) in-house packedwith 1.9 mm
C18 beads (Dr. Maisch, Germany). The column temperature was maintained at 40 C using an integrated column oven (PRSO-V1,
Sonation GmbH, Biberach, Germany). Each peptide fraction was auto-sampled and separated using a 30 min gradient ranging from
10% buffer B (80% ACN and 0.1% formic acid) to 30% B in 25 min and ramped to 45 % B in 5 min at a flow rate of 350 nL/min. The
washout followed at 80% buffer B for 4 min. The Q-Exactive HF mass spectrometer was operated in data-dependent acquisition
mode. Spray voltage was set to 2 kV, s-lens RF level at 50, and heated capillary temperature at 275 C. All experiments were per-
formed in the data-dependent acquisition mode to automatically isolate and fragment topN multiply-charged precursors according
to their intensities. Former target ions were dynamically for 30 seconds excluded and all experiments were acquired using positive
polarity mode. Full scan resolution was set to 60,000 at m/z 200 and the mass range was set to m/z 350-1400. Full scan ion target
value was 3E6 allowing amaximumfill time of 100ms. Higher-energy collisional dissociation (HCD)(Olsen et al., 2007) fragment scans
was acquired with optimal setting for parallel acquisition using 1.3 m/z isolation width and normalized collision energy of 28. For fast-
est HCD-MS/MS scanning a top20 method was employed with fragment scan resolution of 15,000 and an ion target value of 1E5
allowing maximum filling time of 15 ms. For protease comparisons, LC-MS/MS experiments were analyzed with a mix of 30 min
and 60 min LC gradients and full scan resolutions at 120,000 at m/z 200 with a maximum fill time of 25 ms. For 60 min gradients,
fast scanning top12 method using 30,000 resolution for HCD scans with maximum fill time of 45 ms was acquired. Phosphopep-
tide-enriched samples were analyzed with a sensitive top7 scanning method. Ion target value for HCD fragment scans were set
to 2E5 with a maximum fill time of 110 ms and analyzed with 60,000 resolution.
Next-Generation RNA-Seq
Paired end mRNA sequencing was performed as previously described (Ongen et al., 2014) using the Illumina Hiseq 2000 Platform. In
brief, 500 ng total RNA was used for library preparation with the TruSeq RNA Sample Prep Kit v2 and the libraries had fragment
lengths of 200bp. TruSeq PE Cluster Kit v3 was used for cluster generation, and TruSeq SBS Kit v3 for sequencing. Human tran-
scriptome quantification was performed by trimming read adaptor sequences using the AdapterRemoval tool (https://github.com/
slindgreen/AdapterRemoval) mapping the reads to the human genome issue HG19 (hg19) using the Tophat2 mapper (Kim et al.,
2013) and estimating FPKM values for Ensembl genes using Cufflink (Gencode v15 annotation w/o Pseudogenes) (Trapnell
et al., 2010).
QUANTIFICATION AND STATISTICAL ANALYSIS
Raw Data Processing and Analysis
All raw LC–MS/MS data were analyzed by MaxQuant v1.5.3.6 using the Andromeda Search engine and searched against the
complete human UniProt database including all Swiss-Prot and TrEMBL entries as well as all isoforms. In addition, the default
contaminant protein database was included and any hits to this excluded from further analysis. The second peptide option was
disabled and ‘‘match between runs’’ features were excluded in the downstream analysis. Two previously published dataset were
included as raw-files in our combined MaxQuant analysis. These are three 14 fraction HeLa experiments (Kelstrup et al., 2014)
and three human tissues (Kim et al., 2014). Four analysis groups were made in MaxQuant, enabling one combined analysis for alle3 Cell Systems 4, 587–599.e1–e4, June 28, 2017
proteases. Carbamidomethylation of cysteine was specified as fixed modification for all groups. Variable modifications considered
were oxidation of methionine, protein N-terminal acetylation, pyro-glutamate formation from glutamine and phosphorylation of
serine, threonine, and tyrosine residues. For PTM analysis, the HeLa dataset was searched separately using methylation of argnines
and lysines or acetylation of lysines as variable modifications.
False Discovery Rate (FDR) Analysis
The false discovery rate (FDR) was set to 1% on PSM, PTM site and Protein level. The FDR control employed in MaxQuant has
recently been described in detail (Tyanova et al., 2016a). Briefly, MaxQuant make use of the target-decoy search strategy to estimate
and control the extent of false-positive identifications using the concept of posterior error probability (PEP) to integrate multiple pep-
tide properties, such as length, charge, number of modifications, and Andromeda score into a single quantity reflecting the quality of
a peptide spectrum match (PSM). A second level of FDR control is set on the list of reported protein groups by calculating a Protein
group score. This is the product of individual PEPs of the peptides of a protein group, and includes a factor to take into account the
number of peptides per protein group. The protein group score is similar to the PEP, in that it provides a measure of the certainty of
protein identification.
When analyzing multiple different cell lines, tissue samples and external datasets together in MaxQuant compared to analyzing the
datasets individually, themain difference lies in the calculation of the protein FDR, which is done globally based on all raw files. This is
important because if search results for separate raw files or datasets are combined into one larger dataset without any further higher-
level FDR control; false-positive protein identifications are known to aggregate. As the computational performance of MaxQuant
scales very well with the number of raw files it is recommended to always analyze all raw files that will later be used in a comparative
manner together in a singleMaxQuant. This has the additional advantage that the protein groups are defined in common for thewhole
data set, which simplifies quantitative comparative analysis of protein ratios and intensities.
Bioinformatics Analysis
The majority of the bioinformatics was accomplished using custom Perl and R scripts supplemented with Perseus (Tyanova et al.,
2016b). Pathway visualization was done using PathVisio 3.2.2 (Kutmon et al., 2015). The String (Szklarczyk et al., 2015) database
version 10 was read into Cytoscape (www.cytoscape.org) for visualization of complexes. External datasets used were proteome
and RNAseq data from HeLa (Nagaraj et al., 2011), the Corum (Ruepp et al., 2010) database release February 2012 limited to human
species, citation numbers were obtained from PhosphoSite.org (Hornbeck et al., 2004), and HeLa copy number estimates (Hanke
et al., 2008; Zeiler et al., 2012). Mapping of gene and protein identifiers between experiments were done as follows. All identifiers
from UniProt, IPI, and older Ensembl identifiers were mapped to protein-coding genes in the Ensembl database version 84 primary
assembly based on GRCh38. The primary gene identifier for each protein group was defined as the ones that represented proteins
that could explain all peptides within a protein group. Overlap between datasets was calculated based on match to primary gene
identifier. When a gene identifier represents multiple protein groups, the highest number of razor and unique peptides is used to
choose the group of the main protein-coding gene. PTM site sequence motif analysis was performed using IceLogo (Colaert
et al., 2009)with fold-change as the scoring system and a p-value cut-off of 0.05. Our input dataset was sequence windows for in-
dividual PTM sites identified and the complete human dataset were used as the background dataset.
DATA AND SOFTWARE AVAILABILITY
All raw mass spectrometric data files from this study have been deposited to the ProteomeXchange Consortium via the PRIDE part-
ner repository (Vizcaino et al., 2014) with the dataset identifier PXD004452.Cell Systems 4, 587–599.e1–e4, June 28, 2017 e4
